On 26 February 2019, orphan designation (EU/3/19/2137) was granted by the European Commission to Enzyvant Therapeutics Ireland Limited, Ireland, for allogeneic cultured postnatal thymus-derived tissue (also known as RVT-802) for the treatment of severe combined immunodeficiency due to FOXN1 deficiency.
Allogeneic cultured postnatal thymus-derived tissue
|Disease / condition||
Treatment of severe combined immunodeficiency due to FOXN1 deficiency
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: